Pyrazole carboxamide compounds and methods of use
AssigneeGenentech, Inc.
InventorsRoland J. BILLEDEAU, James J. CRAWFORD, Saul JAIME-FIGUEROA, Wendy LEE, Francisco Javier LOPEZ-TAPIA, Sung-Sau SO
Life of this patent
Estimating the term…
Abstract
Pyrazole carboxamide compounds of Formula I are provided, with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Claims13
A compound selected from Formula I:
- or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein:
- X is CH
- R1, R2 and R3 are independently selected from H, —C(O)NH2, C6-C20 aryl, C3-C12 carbocyclyl, C2-C20 heterocyclyl, C1-C20 heteroaryl, —NH2, —NH—(C6-C20 aryl), —NH—(C1-C20 heteroaryl), —C(O)—(C1-C12 alkyl), —C(O)—(C3-C12 carbocyclyl), —NH—(C1-C12 alkylene)-(C2-C20 heterocyclyl), —NH—(C1-C20 heteroaryl)-(C2-C20 heterocyclyl), —NHC(O)—(C3-C12 carbocyclyl), —NHC(O)—(C1-C12 alkyl), —(C6-C20 aryl)-C(O)—(C2-C20 heterocyclyl), and —(C1-C20 heteroaryl)-(C2-C20 heterocyclyl);
- at least one of R1, R2 and R3 is —C(O)NH2;
- R4 is selected from H, F, Cl, CN, —CH2OH, —CH(CH3)OH, —C(CH3)2OH, —CH(CF3)OH, —CH2F, —CHF2, —CH2CHF2, —CF3, —C(O)NH2, —C(O)NHCH3, —C(O)N(CH3)2, —NH2, —NHCH3, —N(CH3)2, —NHC(O)CH3, —OH, —OCH3, —OCH2CH3, —OCH2CH2OH, cyclopropyl, cyclopropylmethyl, 1-hydroxycyclopropyl, imidazolyl, pyrazolyl, 3-hydroxy-oxetan-3-yl, oxetan-3-yl, and azetidin-1-yl;
- R5 is H, F, Cl, or CN;
- R6 is selected from the structures:
- where the wavy line indicates the site of attachment;
- and
- alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, —CN, —CH3, —CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2NH2, —CH2NHCH3, —CH2N(CH3)2, —CH2OH, —CH2OCH3, —CH2CH2OH, —C(CH3)2OH, —CH(OH)CH(CH3)2, —C(CH3)2CH2OH, —CH2CH2SO2CH3, —CH2OP(O)(OH)2, —CH2F, —CHF2, —CF3, —CH2CF3, —CH2CHF2, —CH(CH3)CN, —C(CH3)2CN, —CH2CN, —CO2H, —COCH3, —CO2CH3, —CO2C(CH3)3, —COCH(OH)CH3, —CONH2, —CONHCH3, —CON(CH3)2, —CONH(CH2CH2N(CH3)2), —C(CH3)2CONH2, —NH2, —NHCH3, —N(CH3)2, —NHCOCH3, —N(CH3)COCH3, —NHS(O)2CH3, —N(CH3)C(CH3)2CONH2, —N(CH3)CH2CH2S(O)2CH3, —NO2, ═O, —OH, —OCH3, —OCH2CH3, —OCH2CH2OCH3, —OCH2CH2OH, —OCH2CH2N(CH3)2, —OP(O)(OH)2, —S(O)2N(CH3)2, —SCH3, —S(O)2CH3, —S(O)3H, cyclopropyl, oxetanyl, azetidinyl, 1-methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-yl amino, azetidin-1-ylmethyl, pyrrolidin-1-yl, and morpholino.
-3. (canceled)
The compound of claim wherein R3 is —C(O)NH2.
-31. (canceled)
Dependencies are inferred from the claim text.